Insider · CIK 0001763494

Dube Eric M

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001763494

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+43.7K sh	$26.88	+$1.18M	476,621
2026-10-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+200K sh	$8.93	+$1.79M	676,621
2026-10-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−128K sh	$52.97	−$6.78M	548,556
2026-10-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−37.3K sh	$54.20	−$2.02M	511,286
2026-10-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−78.4K sh	$55.02	−$4.31M	432,886
2026-10-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−43.7K sh	—	—	168,925
2026-10-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−200K sh	—	—	160,000
2026-09-17	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+108K sh	$23.34	+$2.53M	541,379
2026-09-17	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−102K sh	$64.59	−$6.57M	439,688
2026-09-17	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−6,802 sh	$64.95	−$442K	432,886
2026-09-17	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−108K sh	—	—	0
2026-09-16	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+196K sh	$23.34	+$4.57M	628,727
2026-09-16	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−99.7K sh	$63.26	−$6.31M	529,011
2026-09-16	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−96.1K sh	$63.64	−$6.12M	432,886
2026-09-16	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−196K sh	—	—	108,493
2026-09-15	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+95.7K sh	$23.34	+$2.23M	528,552
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−63.5K sh	$61.99	−$3.94M	465,054
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−28.8K sh	$62.66	−$1.8M	436,258
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−3,102 sh	$63.64	−$197K	433,156
2026-09-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−270 sh	$65.31	−$17.6K	432,886
2026-09-15	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−95.7K sh	—	—	304,334
2026-05-06	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−22.5K sh	$43.95	−$989K	432,886
2026-05-04	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+22.5K sh	—	—	455,386
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsA Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+45K sh	—	—	45,000
2026-05-04	TVTXTravere Therapeutics, Inc. · Performance-based restricted stock unitsM Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−22.5K sh	—	—	22,500
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−56.8K sh	$41.01	−$2.33M	440,071
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−7,165 sh	$41.75	−$299K	432,906
2026-04-15	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−20 sh	$42.66	−$853.2	432,886
2026-04-13	TVTXTravere Therapeutics, Inc.A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+64K sh	—	—	496,886
2026-04-01	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+60K sh	$15.46	+$928K	492,886
2026-04-01	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−34.9K sh	$30.55	−$1.07M	457,984
2026-04-01	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−25.1K sh	$31.46	−$790K	432,886
2026-04-01	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−60K sh	—	—	0
2026-02-20	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+60K sh	$15.46	+$928K	492,886
2026-02-20	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−60K sh	$30.10	−$1.81M	432,886
2026-02-20	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−60K sh	—	—	60,000
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−66.5K sh	$32.06	−$2.13M	466,521
2026-02-03	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−33.6K sh	$32.70	−$1.1M	432,886
2026-01-31	TVTXTravere Therapeutics, Inc.A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+114K sh	—	—	532,973
2026-01-31	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)A Award	Director, CHIEF EXECUTIVE OFFICER	AAward	+304K sh	—	—	303,600
2026-01-27	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+51.9K sh	$15.46	+$802K	471,038
2026-01-27	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−51.9K sh	$30.10	−$1.56M	419,173
2026-01-27	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−51.9K sh	—	—	120,000
2026-01-23	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+8,135 sh	$15.46	+$126K	427,308
2026-01-23	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−8,135 sh	$30.01	−$244K	419,173
2026-01-23	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−8,135 sh	—	—	171,865
2025-10-29	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+27.1K sh	$15.46	+$419K	446,301
2025-10-29	TVTXTravere Therapeutics, Inc.S Sale	Director, CHIEF EXECUTIVE OFFICER	SSale	−27.1K sh	$30.12	−$817K	419,173
2025-10-29	TVTXTravere Therapeutics, Inc. · Employee stock option (right to buy)M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	−27.1K sh	—	—	180,000
2025-10-28	TVTXTravere Therapeutics, Inc.M Exercise/Conversion	Director, CHIEF EXECUTIVE OFFICER	MExercise/Conversion	+92.9K sh	$15.46	+$1.44M	512,045

Recent filings

Accepted (ET)
Oct 194
Dube Eric M0001763494-26-000008
SEC(opens sec.gov)
Sep 174
Dube Eric M0001763494-26-000007
SEC(opens sec.gov)

Companies

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300

SAN DIEGO, CA, 92130